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Letters to the Editor
Histopathological data
Sir
We read with interest the recent paper by Pichon MF et al (1996).
We first noted that the following histopathological data had
been used in this study: tumour classification, tumour grading,
maximum tumour diameter and axillary lymph node status. These
data were derived from the records of the pathological examina-
tion of2257 tumorectomies or mastectomies. We then noticed that
the histology slides had apparently not been reviewed by a panel
of pathologists. Surely, this has become an indispensable way of
ensuring a minimum ofquality control in any multicentre study of
this type. Being further aware that the authors ofthis paper did not
include a single pathologist, we were dismayed by the complete
lack of any reference to the several pathologists who had obvi-
ously contributed to this monumental series.
We wish to strongly urge editors and referees of international
oncology journals, when reviewing multicentre studies primarily
based on histopathological data, to ensure that such papers are
adequately reviewed by a panel of pathologists and that the
identity and affiliation of contributing or panelist pathologists are
clearly indicated.
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Histopathological data-
reply
Sir
The aim of our study, using the data of medical records obtained
under the conditions of current medical practice, was to evaluate
the relationship between the results of quantitative measurements
of hormone receptors in primary tumours and the occurrence of
events during the monitoring of breast cancers. In French Cancer
Centres, the diagnosis, treatment and monitoring ofbreast cancers
is carried out by multidisciplinary teams made up of specialists
who all contribute to the elaboration of the medical records
common to the Institution.
This paper did not purport to focus on histological correlations,
which merely represent four out ofnine criteria studied.
Consequently, we saw no case for a specific post-review of
histological data, as the main criteria of this study, oestradiol and
progesterone receptors, were permanently subject to quality
control. This is common standard practice for all laboratories
engaged in steroid receptor assays.
Furthermore, no recent similar studies include post-verification
of histological data (Spyratos et al, 1992; Pujol et al, 1994;
Romain et al, 1995, 1996).
In so far as no further work is required from any other speciality
outside the present team, there is no justification for certain
specialists rather than others in the list ofauthors. In addition, the
majority of this series of patients' records has already been the
object ofprevious publications to which pathologists were associ-
ated (more than 25 papers in all).
MF Pichon
On behalfof
The Group de Biopathologie Tissulaire
et Moleculaire
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BRCAI polymorphisms
Sir
Determining the clinical significance of germline alterations in
BRCAJ has serious implications for predicative assessment of
breast and ovarian cancer risk. While the majority ofalterations in
BRCAJ are frameshift or nonsense mutations that are likely to
damage gene function severely, determining the status of intronic
sequence variants or of rare sequence variants that result in
missense alterations is more difficult and conflicting interpreta-
tions of such variants have been published. We report here on two
such variants which we believe can now be classified as non-
pathological rare sequence variants.
Perhaps the most controversial of these variants is a 12-
nucleotide duplication 48 base pairs downstream of the 3'
boundary ofexon 20. Although this is in aregion unlikely to affect
RNA splicing, it was tentatively classified as a mutation by
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Takahashi et al (1995) because it was found in a woman diagnosed
with both breast and ovarian cancer and who also had five
maternal relatives with breast cancer. Subsequently, the variant
was reported by Langston et al (1996a) in a woman diagnosed
with breast and cervical cancer, and in two independent cases of
prostate cancer (Langston et al, 1996b). In none of these studies
was the alteration observed in 174, 237 and 145 non-cancer
controls respectively. The classification of this variant as a 'defi-
nite' variant by Langston et al (1996a) attracted criticism (Mathew
et al, 1996), as in the absence of a functional test the evidence for
its pathological nature is at best circumstantial.
In the course of our analysis for BRCAJ mutations in 300 cases
ofearly-onset breast cancer or sporadic ovarian cancer we detected
this variant in four apparently unrelated individuals, three diag-
nosed with breast cancer aged 23, 29 and 38 and one with bilateral
mucinous cystadenomata of the ovaries aged 70. None of these
women had a family history ofBRCAI-related cancers apart from
one breast cancer patient whose mother died ofbreast cancer aged
40. In the two other isolated breast cancer cases, in which the
parents were available for analysis, the insertion was inherited
from the mother in one case and from the father in the other.
Consistent with a tumour-suppressor role of BRCAJ, previous
analyses of tumours with loss of heterozygosity at the BRCAJ
locus have revealed that in every case it is the wild-type allele that
is lost (Merajver et al, 1995). However, analysis of tumours from
our cases revealed that all three breast cancers showed loss of
heterozygosity, and in each case it was the 12 bp insertion allele
that was lost (Figure 1), suggesting that the intron 20 insertion is in
fact a rare non-pathological sequence variant.
The second variant we investigated was the missense mutation
designated R1347G caused by an A-*G substitution at nucleotide
4158 first detected in Utah kindred K2039 by Shattuck-Eidens et al
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Figure 1 Loss of heterozygosity analysis of tumours with the 12-bp intron 20
insertion. Normal (N) and tumour (T) DNA was PCR amplified with primers
flanking exon 20 of BRCA1. Normal DNA was not available for breast cancer
B46. The bands associated with the 12-bp insertion allele are indicated by
arrows. Loss of the 12-bp insertion allele can be seen in the three breast
cancers. The benign ovarian tumour, 075, retained heterozygosity at this locus
(1995). This variant was not detected in 232 controls, but the indi-
vidual carrying this alteration also had a frameshift mutation,
casting doubt on its pathological significance.
We have detected the R1347G in nine apparently unrelated
cases of early-onset breast cancer. In two of these cases we also
detected frameshift mutations caused by a 1 bp deletion at nucleo-
tide 2594 in one and a4 bp deletion at nucleotide 3875 in the other.
In the former case, DNA was available from the mother, who was
found to be carrying the 1 bp deletion at 2594 but not the R1347G
variant. In contrast to the strong family history of breast and
ovarian cancer on the maternal side (one ovarian cancer, three
breast cancers, one colon cancer and one stomach cancer among
18 first- and second-degree relatives) there were no reported
cancers among nine first- and second-degree relatives on the
paternal side, including the father and two aunts, who were over
the age of70.
Among the other carriers of the R1347G variant four had no
family history of cancer. The remaining three cases had family
histories consistent with inherited BRCAJ orBRCA2 mutations but
the analysis of these genes is incomplete. We conclude that
R1347G is a non-pathological sequence variant that may have its
origins in the south ofEngland.
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